chemed corp. - CHE
CHE
Close Chg Chg %
562.96 8.89 1.58%
Closed Market
571.85
+8.89 (1.58%)
Volume: 113.34K
Last Updated:
Nov 22, 2024, 3:59 PM EDT
Company Overview: chemed corp. - CHE
CHE Key Data
| Open $565.54 | Day Range 562.06 - 572.83 |
| 52 Week Range 523.33 - 654.62 | Market Cap $8.44B |
| Shares Outstanding 14.98M | Public Float 14.71M |
| Beta 0.46 | Rev. Per Employee N/A |
| P/E Ratio 28.48 | EPS $20.00 |
| Yield 30.18% | Dividend $0.50 |
| EX-DIVIDEND DATE Nov 18, 2024 | SHORT INTEREST N/A |
| AVERAGE VOLUME 108.25K |
CHE Performance
| 1 Week | 2.33% | ||
| 1 Month | -5.31% | ||
| 3 Months | -0.25% | ||
| 1 Year | -1.54% | ||
| 5 Years | 34.47% |
CHE Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About chemed corp. - CHE
Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.
CHE At a Glance
Chemed Corp.
255 East 5th Street
Cincinnati, Ohio 45202-4726
| Phone | 1-513-762-6690 | Revenue | 2.26B | |
| Industry | Hospital/Nursing Management | Net Income | 272.51M | |
| Sector | Health Services | 2023 Sales Growth | 6.064% | |
| Fiscal Year-end | 12 / 2024 | Employees | 15,087 | |
| View SEC Filings |
CHE Valuation
| P/E Current | 28.478 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 32.616 |
| Price to Sales Ratio | 3.925 |
| Price to Book Ratio | 7.936 |
| Price to Cash Flow Ratio | 26.91 |
| Enterprise Value to EBITDA | 21.747 |
| Enterprise Value to Sales | 3.877 |
| Total Debt to Enterprise Value | 0.018 |
CHE Efficiency
| Revenue/Employee | 150,090.608 |
| Income Per Employee | 18,062.504 |
| Receivables Turnover | 12.475 |
| Total Asset Turnover | 1.372 |
CHE Liquidity
| Current Ratio | 1.605 |
| Quick Ratio | 1.567 |
| Cash Ratio | 0.846 |
CHE Profitability
| Gross Margin | 32.589 |
| Operating Margin | 15.14 |
| Pretax Margin | 15.473 |
| Net Margin | 12.034 |
| Return on Assets | 16.516 |
| Return on Equity | 28.586 |
| Return on Total Capital | 21.577 |
| Return on Invested Capital | 24.657 |
CHE Capital Structure
| Total Debt to Total Equity | 14.001 |
| Total Debt to Total Capital | 12.281 |
| Total Debt to Total Assets | 8.809 |
| Long-Term Debt to Equity | 9.096 |
| Long-Term Debt to Total Capital | 7.979 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Chemed Corp. - CHE
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 2.08B | 2.14B | 2.13B | 2.26B | |
Sales Growth
| +7.27% | +2.87% | -0.20% | +6.06% | |
Cost of Goods Sold (COGS) incl D&A
| 1.43B | 1.43B | 1.43B | 1.53B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 56.58M | 59.05M | 59.17M | 60.87M | |
Depreciation
| 46.60M | 49.01M | 49.10M | 50.80M | |
Amortization of Intangibles
| 9.99M | 10.04M | 10.07M | 10.06M | |
COGS Growth
| +5.01% | -0.44% | +0.04% | +6.82% | |
Gross Income
| 644.80M | 710.75M | 705.91M | 737.95M | |
Gross Income Growth
| +12.68% | +10.23% | -0.68% | +4.54% | |
Gross Profit Margin
| +31.01% | +33.22% | +33.06% | +32.59% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 330.22M | 368.58M | 358.73M | 395.12M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 330.22M | 368.58M | 358.73M | 395.12M | |
SGA Growth
| +9.75% | +11.62% | -2.67% | +10.15% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (75.64M) | (41.12M) | 2.61M | 2.05M | |
EBIT after Unusual Expense
| 390.22M | 383.29M | 344.57M | 340.78M | |
Non Operating Income/Expense
| 8.12M | (31.10M) | (10.31M) | 12.70M | |
Non-Operating Interest Income
| 757.00K | 377.00K | 355.00K | 6.27M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 2.35M | 1.87M | 4.58M | 3.11M | |
Interest Expense Growth
| -48.07% | -20.68% | +145.40% | -32.20% | |
Gross Interest Expense
| 2.35M | 1.87M | 4.58M | 3.11M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 395.99M | 350.31M | 329.68M | 350.37M | |
Pretax Income Growth
| +51.37% | -11.53% | -5.89% | +6.28% | |
Pretax Margin
| +19.04% | +16.38% | +15.44% | +15.47% | |
Income Tax
| 76.52M | 81.76M | 80.06M | 77.86M | |
Income Tax - Current - Domestic
| 74.55M | 78.85M | 64.72M | 85.32M | |
Income Tax - Current - Foreign
| 539.00K | 511.00K | 505.00K | 569.00K | |
Income Tax - Deferred - Domestic
| 1.46M | 2.36M | 14.82M | (8.03M) | |
Income Tax - Deferred - Foreign
| (23.00K) | 42.00K | 6.00K | 2.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 319.47M | 268.55M | 249.62M | 272.51M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 319.47M | 268.55M | 249.62M | 272.51M | |
Net Income Growth
| +45.26% | -15.94% | -7.05% | +9.17% | |
Net Margin Growth
| +15.36% | +12.55% | +11.69% | +12.03% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 319.47M | 268.55M | 249.62M | 272.51M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 319.47M | 268.55M | 249.62M | 272.51M | |
EPS (Basic)
| 20.0229 | 17.1368 | 16.7207 | 18.1069 | |
EPS (Basic) Growth
| +45.39% | -14.41% | -2.43% | +8.29% | |
Basic Shares Outstanding
| 15.96M | 15.67M | 14.93M | 15.05M | |
EPS (Diluted)
| 19.482 | 16.8497 | 16.5325 | 17.9282 | |
EPS (Diluted) Growth
| +46.41% | -13.51% | -1.88% | +8.44% | |
Diluted Shares Outstanding
| 16.40M | 15.94M | 15.10M | 15.20M | |
EBITDA
| 371.17M | 401.22M | 406.36M | 403.69M | |
EBITDA Growth
| +17.25% | +8.10% | +1.28% | -0.66% | |
EBITDA Margin
| +17.85% | +18.76% | +19.03% | +17.83% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 685.00 | |
| Number of Ratings | 4 | Current Quarters Estimate | 6.783 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 23.08 | |
| Last Quarter’s Earnings | 5.64 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 20.30 | Next Fiscal Year Estimate | 24.89 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 3 | 3 |
| Mean Estimate | 6.78 | 5.56 | 23.08 | 24.89 |
| High Estimates | 6.84 | 5.80 | 23.13 | 25.55 |
| Low Estimate | 6.74 | 5.33 | 23.05 | 24.48 |
| Coefficient of Variance | 0.76 | 4.23 | 0.19 | 2.32 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Buy |
SEC Filings for Chemed Corp. - CHE
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Chemed Corp. - CHE
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 24, 2024 | Spencer S. Lee executive vice president | 24,542 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 24, 2024 | Kevin J. McNamara president and CEO; Director | 217,487 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 24, 2024 | Michael D. Witzeman VP & Chief Financial Officer | 43,280 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 24, 2024 | Nicholas M. Westfall Executive Vice President | 62,260 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 27, 2024 | George J. Walsh Director | 3,046 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $597.47 per share | 1,819,893.62 |
| Jun 14, 2024 | Patrick P. Grace Director | 3,270 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $540.98 per share | 1,769,004.60 |
| May 22, 2024 | Eileen P Mccarthy Director | 578 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share | 326,188.52 |
| May 22, 2024 | Christopher J. Heaney Director | 2,112 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share | 1,191,886.08 |
| May 22, 2024 | John M. Mount Director | 653 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share | 368,514.02 |
| May 22, 2024 | Andrea R. Lindell Director | 6,556 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share | 3,699,813.04 |
| May 22, 2024 | Thomas P. Rice Director | 6,028 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share | 3,401,841.52 |
| May 21, 2024 | Ron DeLyons Director | 1,389 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $564.34 per share | 783,868.26 |
| May 9, 2024 | Michael D. Witzeman VP & Chief Financial Officer | 37,833 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 9, 2024 | Michael D. Witzeman VP & Chief Financial Officer | 3,061 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $576.95 per share | 1,766,043.95 |
| Mar 8, 2024 | Thomas C. Hutton vice president; Director | 15,857 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 8, 2024 | Thomas C. Hutton vice president; Director | 17,857 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 8, 2024 | Thomas C. Hutton vice president; Director | 36,919 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $633.58 per share | 23,391,140.02 |
| Mar 8, 2024 | Thomas C. Hutton vice president; Director | 39,592 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $471.74 per share | 18,677,130.08 |
| Mar 8, 2024 | Thomas C. Hutton vice president; Director | 37,592 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $413.19 per share | 15,532,638.48 |
| Feb 21, 2024 | Thomas C. Hutton vice president; Director | 926 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |